Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NETWORK × Methoxsalen × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

OTHER 3 NIH 1 NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1 Dermatologic 1

Conditions

Sezary Syndrome 1 Mycosis Fungoides 1 Lymphoma, T-Cell, Cutaneous 1

Interventions

Cisplatin 110 Radiotherapy 105 Paclitaxel 78 Cyclophosphamide 76 Gemcitabine 67 Carboplatin 62 Filgrastim 50 Etoposide 49 Doxorubicin 49 Docetaxel 49 Fluorouracil 47 Vincristine 44 Cytarabine 36 Leucovorin 35 Capecitabine 35 Methotrexate 34 Dexamethasone 34 Prednisone 33 Irinotecan 33 Oxaliplatin 27 Rituximab 24 Cetuximab 24 Bevacizumab 24 Temozolomide 23 durvalumab 22 Surgical Procedures, Operative 22 Radiotherapy, Intensity-Modulated 22 Magnetic Resonance Spectroscopy 22 Granulocyte Colony-Stimulating Factor 22 Peripheral Blood Stem Cell Transplantation 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03563040 2021-09-08

PROMPT

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡